Similarly, in a two-center, randomized, parallel-group clinical trial, the effects of exenatide on BMD and bone turnover markers including osteocalcin (OC), C-telopeptide of type I collagen (CTX-1) and tartrate-resistant alkaline phosphatase 5b (TRAcP5b) were compared with insulin or pioglitazone treatment (n = 62, newly diagnosed T2D patients). The gene discussed is INS; the disease is type 2 diabetes mellitus.